Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer

References

• Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, Graff RE, Holst K, Möller S, Unger RH, et al. Familial risk and heritability of cancer among twins in nordic countries. JAMA. 2016;315(1):68–76. doi:10.1001/jama.2015.17703.
   PubMed Web of Science ®Google Scholar
• Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin M-E, Pritchard C, Attard G, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–1228. doi:10.1016/j.cell.2015.05.001.
   PubMed Web of Science ®Google Scholar
• Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443–453. doi:10.1056/NEJMoa1603144.
   PubMed Web of Science ®Google Scholar
• Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2010;16(7):2115–2121. doi:10.1158/1078-0432.CCR-09-2871.
   PubMed Web of Science ®Google Scholar
• Leongamornlert D, Saunders E, Dadaev T, Tymrakiewicz M, Goh C, Jugurnauth-Little S, Kozarewa I, Fenwick K, Assiotis I, Barrowdale D, et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer. 2014;110(6):1663–1672. doi:10.1038/bjc.2014.30.
   PubMed Web of Science ®Google Scholar
• Olive PL. The role of DNA single- and double-strand breaks in cell killing by ionizing radiation. Radiat Res. 1998;150:S42–S51. doi:10.2307/3579807.
   PubMed Web of Science ®Google Scholar
• Povirk LF, Wübker W, Köhnlein W, Hutchinson F. DNA double-strand breaks and alkali-labile bonds produced by bleomycin. Nucleic Acids Res. 1977;4:3573–3580. doi:10.1093/nar/4.10.3573.
   PubMed Web of Science ®Google Scholar
• Wallace SS. Enzymatic processing of radiation-induced free radical damage in DNA. Radiat Res. 1998;150:S60–S79. doi:10.2307/3579809.
   PubMed Web of Science ®Google Scholar
• Scully R, Panday A, Elango R, Willis NA. DNA double-strand break repair-pathway choice in somatic mammalian cells. Nat Rev Mol Cell Biol. 2019;20:698–714. doi:10.1038/s41580-019-0152-0.
   PubMed Web of Science ®Google Scholar
• Lee J-H, Paull TT. Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. Science. 2004;304:93–96. doi:10.1126/science.1091496.
   PubMed Web of Science ®Google Scholar
• Lee J-H, Paull TT. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 COMPLEX. Science. 2005;308:551–554. doi:10.1126/science.1108297.
   PubMed Web of Science ®Google Scholar
• Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett L, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66–71. doi:10.1126/science.7545954.
   PubMed Web of Science ®Google Scholar
• Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789–792. doi:10.1038/378789a0.
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–1392. doi:10.1056/NEJMoa1105535.
   PubMed Web of Science ®Google Scholar
• Iglehart JD, Silver DP. Synthetic lethality — a new direction in cancer-drug development. N Engl J Med. 2009;361:189–191. doi:10.1056/NEJMe0903044.
   PubMed Web of Science ®Google Scholar
• Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697–1708. doi:10.1056/NEJMoa1506859.
   PubMed Web of Science ®Google Scholar
• Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26:3785–3790. doi:10.1200/JCO.2008.16.0812.
   PubMed Web of Science ®Google Scholar
• Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J clin oncol. 2015;33(3):244–250. doi:10.1200/JCO.2014.56.2728.
   PubMed Web of Science ®Google Scholar
• Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami K, Guy M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J clin oncol. 2013;31(14):1748–1757. doi:10.1200/JCO.2012.43.1882.
   PubMed Web of Science ®Google Scholar
• Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, Syndikus I, Ralph C, Jain S, Varughese M, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):162–174. doi:10.1016/S1470-2045(19)30684-9.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Study on olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer. US National Library of Medicine ClinicalTrials.gov. 2018.
   Google Scholar
• Addenbrooke’s Hospital CUHFT. Study of olaparib (±Degarelix) given to men with intermediate/high risk prostate cancer before prostatectomy (CaNCaP03). US National Library of Medicine ClinicalTrials.gov. 2014.
   Google Scholar
• Antonarakis E Olaparib in men with high-risk biochemically-recurrent prostate cancer following radical prostatectomy, with integrated biomarker analysis. US National Library of Medicine ClinicalTrials.gov. 2017.
   Google Scholar
• Yu EY, Massard C, Retz M, Tafreshi A, Galceran JC, Hammerer P, Fong PCC, Shore ND, Joshua A, Linch MD, et al. Keynote-365 cohort a: pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol. 2019;37:145. doi:10.1200/JCO.2019.37.7_suppl.145.
   Web of Science ®Google Scholar
• Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, Voog EG, Bryce AH, McDermott R, Ricci F, et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. Clin Cancer Res. 2020;26(11):2487–2496. doi:10.1158/1078-0432.CCR-20-0394.
   PubMed Web of Science ®Google Scholar
• Excellence OCo. FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer. US Food Drug Administration. 2020. https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate.
   Google Scholar